ClinicalTrials.gg
RecruitingNCT05588063kidNEY-VNSUpdated Apr 15, 2026

taVNS for FRNS in Children

An interventional study of Transcutaneous auricular vagus nerve stimulation and Sham device in Nephrotic Syndrome in Children, Minimal Change Disease and Focal Segmental Glomerulosclerosis, sponsored by Northwell Health. Recruiting at 2 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Nephrosis, Lipoid with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrosis, Lipoid · United States.

Planned enrollment
10th of 18
30 · median 31
Started
2023
with 1 other
No phase
7 of 25
4 open now
Primary completion
2027-03
later than 2 of 12 live
Registered
17th of 25
by date
Lead sponsor
3 of 25
Northwell Health

Among the 25 studies in Nephrosis, Lipoid with a site in United States, this one is the 10th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 17th registered.

Nephrosis, Lipoid

76 studies on the registry are indexed under Nephrosis, Lipoid; 33 are open to participants now.

Browse Nephrosis, Lipoid studies →

Open to participants now

12 of the 25 studies in Nephrosis, Lipoid with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Nephrosis, Lipoid studies recruiting now, 10 (40%) set no upper age limit and 10 (40%) stop at 75 or younger; 17 take children under 18; none take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Nephrosis, Lipoid with a site in United States, or all of them as a file.
02

Study summary

Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.

Read the detailed description

Study Design A parallel, double blinded, randomized placebo controlled trial comparing daily taVNS use with sham therapy will be conducted in children 3 to17 years of age with FRNS. Thirty participants with FRNS (defined as having 2 or more relapses in 6 months within 6 months of diagnosis or 4 or more relapses in any 12 month period) will be randomized 1 to 1 to taVNS or sham therapy. Participants will be enrolled at two pediatric tertiary hospitals over a two year time period, with completion of the study by year three. All participants will perform daily taVNS therapy (active for taVNS arm or inactive for sham arm) for 5 minutes each day for a total of 26 weeks. Participants will monitor heart rate with each treatment and log home urine results. Participants will be monitored monthly with in person study visits at Weeks 8, 16 and 26 alternating with virtual remote video visits at Weeks 4, 12 and 20. Biosample specimens will be collected at baseline, 8 weeks, 16 weeks and 26 weeks. There will be a follow up period of an additional 26 weeks. All participants will be given the option to receive the active taVNS treatment at the end of the randomized period.

Intervention The device is the Roscoe Medical Transcutaneous Electrical Nerve Stimulation (TENS) 7000 unit, a FDA approved commercially available handheld electrical pulse generator. A custom-produced silicone-equivalent electrode ear clip manufactured at Feinstein will be placed at the cymba concha of the left ear with electrode gel to provide stimulation (or sham) to the auricular branch of the vagus nerve. taVNS will be performed on the left side because there is less of a risk of cardiac side effects. Maximum power density limit calculations were performed based on data from the FDA as a function of pulse width, current amplitude, electrode size, and effective impedance, suggesting an electrode size of greater than 58 mm2 must be used. The custom-made electrodes for this study are larger than this limit, thus ensuring safety. The device will be set to a frequency of 30 Hz and pulse width of 300 μs based on previous literature. All participants in both trials will perform the intervention therapy for 5 minutes each day. The timing and duration of treatment are based upon the known half-life of the biological cytokine response, previous literature demonstrating efficacy of daily 5 minute treatments and our prior work. The study period will be 26 weeks. This time period was chosen based on the definition of FRNS using a 6-month period, prior clinical trials and ethical concerns for enrolling placebo controls for a longer period of time. All participants will be told that they may or may not feel stimulation from the device. Participants will be asked not to mention any aspects of the stimulation procedures to study investigators/physicians (except to the trainer) to maintain blinding. The device has a Patient Compliance Meter that can record the number of times it was used. This will be used to monitor compliance.

taVNS Group: The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 2.5. In patients who are under the age at which they can verbalize perceptual threshold and tolerability (\<5 years), the investigators will initiate intensity at the lowest setting and incrementally increase the value until the level at which perceptual threshold, defined by changes in facial expression, patient becomes fidgety, or displays behaviors which denote sensation is being perceived. Then, the intensity level will be decreased till the perceptual indicators are no longer present, and the resultant level will be used for the treatment. A maximum power density of 150 milliwatts (mW)/cm2 will be utilized for patients under the age of 5 years, a level that is substantially below the 250 mW/cm2 maximum level defined by the FDA to prevent injury. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.

Sham group: The sham device will be altered internally so that electrical stimulation is not delivered, but the device will appear to function (Feinstein Bioengineering). Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3. This inactive sham method was chosen because previous studies have shown that stimulation with placement of the ear clip on other parts of the ear such as the earlobe, although not innervated by the vagus nerve, results in some vagus nerve activity. Inactive sham methodology has been used in previous studies.

Study Phases The study will consist of three parts. Part 1 - Screening Period- up to 8 weeks. Informed consent/assent will be obtained at screening prior to the conduct of any study-related procedures. Participants will be screened to confirm inclusion/exclusion criteria are met. Participants must be off steroid treatment for 14 days prior to Day 1 and the participant must be in remission (negative urine protein creatinine (UPC) on first morning urine) on Day 1.

Part 2 - Randomized Control Period - 26 weeks: Thirty participants with FRNS who meet all of the eligibility criteria will be randomized 1:1 to either taVNS or sham treatment. A trainer will instruct the parent/guardian on use of the device at the randomization visit. Participants will use the intervention device as directed for 5 minutes per day for 26 weeks. Participants will be monitored monthly with in-person study visits at Weeks 8, 16 and 26 alternating with virtual remote video visits at Weeks 4, 12 and 20. The visit window will be +/- 7 days. At each in person visit, the following will be conducted:

  • Vital signs and physical examination
  • Assessment for nephrotic syndrome relapses. Home urine protein logs will be reviewed.
  • Blood and urine samples will be collected at each in person visit.
  • Assessment of study intervention adherence. Parents/guardians will meet with the trainer and will be reoriented on taVNS device use at each visit as a safety measure. The device counter number will be recorded as a measure of adherence.
  • Monitor for adverse events and tolerability: Parents/guardians will share a study log with investigators, which describes daily taVNS use, side effects, and any changes in heart rate.

At each virtual remote video visit, we will observe the participant while doing the intervention procedure, assess for nephrotic syndrome relapses, and monitor for any adverse events.

There will be a 4 week acclimation phase. If the participant relapses during this period, they will be treated with standard of care steroids and continue the intervention. If the participant relapses a second time or relapses after the acclimation phase, they will be terminated from the randomization phase and entered into the follow up period.

Part 3 - Follow Up Period - 26 weeks: At the completion of the randomized period, participants will be followed for an additional 26 weeks to assess clinical status. For those who stop the intervention, study visits will occur in-person during regularly scheduled clinical visits or via telehealth visit every 8 weeks, whichever is sooner. Participants will be assessed for the number of nephrotic syndrome relapses and home urine protein logs will be reviewed. First morning UPC will be recorded. All participants will be given the option to receive the active taVNS treatment at the end of the randomized period. Unblinding of treatment assignment from the randomized phase will not occur prior to consent for open-label use. As open-label extension trials may introduce significant bias, data obtained from these participants will not be considered part of this research and no statistical analysis will be carried out. However, clinical status and safety will continue to be monitored. In person study visits will occur every 8 weeks for those continuing use of taVNS.

Participant Discontinuation/Withdrawal from the Study Participation is completely voluntary and participants may decide to withdraw at any time. If a participant becomes steroid dependent at any point, they will be withdrawn from the study by investigators and offered alternative immunosuppressive therapy as per standard of care. If a participant in the SRNS group has deterioration in clinical status (e.g. worsening edema, rising creatinine), the treating physician may recommend withdrawal from the study at any point.

The pilot trial is not powered to determine statistically significant differences in efficacy endpoints comparing taVNS with sham therapy. Efficacy analyses will be reserved for the subsequent main trial. Rather, sample sizes were chosen to appropriately assess the feasibility, tolerability and variance effect size endpoints of the pilot trials.

03

Conditions studied

  • Nephrotic Syndrome in Children
  • Minimal Change Disease
  • Focal Segmental Glomerulosclerosis

Keywords

  • vagus nerve stimulation
  • pediatric
  • nephrology
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • FRNS
  • Age 3-17 years
  • (eGFR) ≥30 ml/min/1.73 m2
  • Minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) diagnosis (clinical diagnosis or per )
  • sensitive nephrotic syndrome (prior history of remission within 4 weeks of steroid therapy)
  • In remission at time of enrollment (remission defined as UPC \<0.2 or negative dipstick for 3 consecutive days)
  • from the parent or guardian and assent from a minor of ≥ 7. years

Exclusion criteria

Exclusion Criteria:

  • Secondary forms of nephrotic syndrome
  • SRNS
  • dependent nephrotic syndrome (relapse within 14 days of stopping steroids or relapse while on steroids)
  • Exposure to steroids within 14 days of enrollment
  • Receiving any standing (previous exposure > 2 months allowed and/or B cell repletion)
  • Any known inflammatory condition (e.g. systemic lupus erythematosis)
  • History of cardiac disease (arrhythmias, structural/functional abnormalities)
  • Implantable electronic devices
  • Pregnancy
  • Participants/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3 on the dial indicator. The remaining settings will be stored in the device and will not need to be set for each treatment. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.

    Device: Transcutaneous auricular vagus nerve stimulation

  • Sham comparator
    Sham Group

    The sham device will be disabled internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3. This inactive sham method was chosen because previous studies have shown that stimulation with placement of the ear clip on other parts of the ear such as the earlobe, although not innervated by the vagus nerve, results in some vagus nerve activity. Inactive sham methodology has been used in previous studies.

    Device: Sham device

Interventions

  • DeviceTranscutaneous auricular vagus nerve stimulation

    The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.

    Also known as: Roscoe TENS 7000

  • DeviceSham device

    The device will appear to function but no electrical stimulation will be delivered.

    Also known as: Roscoe TENS 7000

06

What researchers measure

Primary outcomes

  1. Success of Pilot Trial

    1. Unsuccessful, main study not practicable (1) None of the benchmarks are met, or (2) One or more of the benchmarks are not met and there is low likelihood of reaching benchmarks even with protocol modifications or (3) Serious adverse events related to the treatment. 2. Probable Success main study practicable with modifications to protocol. One or more of the benchmarks are not met, but there is a high likelihood that the benchmark can be met with protocol modifications. 3. Successful main study practicable without modifications. All of the benchmarks are met.

    Time frame: Baseline through 26 weeks

Secondary outcomes

  1. Proof-of-Concept Decision Criteria using relative risk for relapse

    The decision to move forward with a larger trial will be made based on pre-determined proof of concept decision criteria. Once data from the pilot trial is observed and collected, 1,000 bootstrap resamples with replacement will be carried out to construct the empirical 95% confidence interval (CI) for the relative risk. Using a non-parametric approach, the lower 2.5th percentile and upper 97.5th percentile will be used to construct the CI, and a GO or NO GO decision to conduct the larger scale trial will be made based on a primary end point. The primary end-point is no relapses within 26 weeks. Based on previous literature, it is presumed that 50% in the intervention arm and 25% of those in sham therapy will reach the primary end-point in each trial, which is equivalent to a relative risk of 2.0.

    Time frame: Baseline through 26 weeks

  2. Estimates of Variance for proportion with nephrotic syndrome relapse

    Frequency counts and proportions with 95 percent confidence intervals

    Time frame: Baseline through 26 weeks

  3. Estimates of Variance for time to nephrotic syndrome relapse

    Mean and standard deviation

    Time frame: Baseline through 26 weeks

  4. Estimates of Variance for time to achieve remission once a relapse occurs

    Mean and standard deviation

    Time frame: Baseline through 26 weeks

  5. Recruitment rate

    Percent

    Time frame: Baseline through 26 weeks

  6. Drop out rate

    Percent

    Time frame: Baseline through 26 weeks

  7. Rate of completion of study

    Percent

    Time frame: Baseline through 26 weeks

  8. Successful double-blinding

    Percent

    Time frame: Baseline through 26 weeks

  9. Treatment adherence from home logs

    Percent

    Time frame: Baseline through 26 weeks

  10. Adverse events

    Percent

    Time frame: Baseline through 26 weeks

  11. Incidence of withdrawal due to adverse events

    Percent

    Time frame: Baseline through 26 weeks

  12. Cytokines

    Tumor necrosis factor (TNF), interleukin (IL)-6 mean and standard deviation

    Time frame: Baseline through 26 weeks

  13. Anti-nephrin antibodies

    Mean and standard deviation

    Time frame: Baseline through 26 weeks

  14. Whole monocyte stimulation assay

    Intracellular cytokines at 0 and 2 hours

    Time frame: 0 hour and 2 hours

07

Study locations

2 of 2 sites recruiting
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
    Recruiting
    • Suzanne Vento, RN · Contactsvento@northwell.edu · 718-470-3491
    • Christine Sethna, MD, EdM · Principal investigator
    • Kevin Tracey, MD · Sub investigator
    • Sangeeta Chavan, PhD · Sub investigator
    • Timir Datta-Chaudhuri, PhD · Sub investigator
    • Stavros Zanos, MD, PhD · Sub investigator
    • Cliff Deutschman, MD, PhD · Sub investigator
    • Joanna FIshbein, MS · Sub investigator
    • Martin Lesser, PhD · Sub investigator
    • Matthew Taylor, MD · Sub investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19102, United States
    Recruiting
    • Kevin Meyers, MD · Contactmeyersk@chop.edu · 215-590-2449
    • Kevin Meyers, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Informed consent documents for the clinical trials will be available on clinical trials.gov. Data will be available from the PI.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Within 12 months of study closure

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Oct 20, 2022
StartActual
Jan 5, 2023
Primary completionEst.
Mar 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05588063
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Jan 5, 2023
Primary completion
Mar 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Christine B Sethna, MD, EdM
Contact
csethna@northwell.edu
718-470-3491
Suzanne Vento, RN
Contact
svento@northwell.edu
718-470-3491

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion